Program
aficamten
Also written as “Aficamten”, “BAY3723113” and “Aficamten (5 - 20 mg)”.
Its studies are mostly in Cardiomyopathy, Hypertrophic, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Cytokinetics | 83 open or running | phase 3since Apr 9, 2021 | Dec 3, 2018 | Mar 2029phase 3 · NCT04848506 |
| Corxel Pharmaceuticals | 20 open or running | phase 3since Oct 25, 2023 | Mar 3, 2021 | none ahead |
| Bayer | 11 open or running | phase 3since Jun 10, 2025 | Jun 10, 2025 | none ahead |
Also a collaborator on its studies: Sanofi.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 3, 2018First study: phase 1 study in Cardiomyopathy, HypertrophicNew to CytokineticsCytokinetics · NCT03767855 · 114 enrolled · United States
- Jan 3, 2020Phase 2 study in Cardiomyopathy, HypertrophicCytokinetics · NCT04219826 · 96 enrolled · United States, Italy, Netherlands and more
- Mar 3, 2021Corxel Pharmaceuticals's first study: phase 1 study in Cardiomyopathy, HypertrophicNew to Corxel PharmaceuticalsCorxel Pharmaceuticals · NCT04783766 · 28 enrolled · China
- Apr 9, 2021Phase 3 study in Cardiomyopathy, HypertrophicCytokinetics · NCT04848506 · 900 planned · United States, Argentina, Australia and more
- Dec 23, 2021Phase 3 study in Cardiomyopathy, HypertrophicCytokinetics · NCT05186818 · 282 enrolled · United States, China, Czechia and more
- Mar 2, 2023Phase 3 study in Cardiomyopathy, HypertrophicCytokinetics · NCT05767346 · 175 enrolled · United States, Brazil, Canada and more
- Jun 7, 2023Phase 1 study in Healthy ParticipantsCytokinetics · NCT05924815 · 44 enrolled · United States
- Aug 31, 2023Phase 3 study in Symptomatic Non-Obstructive Hypertrophic CardiomyopathyCytokinetics · NCT06081894 · 500 enrolled · United States, Argentina, Australia and more
- Oct 25, 2023Phase 3 study in Cardiomyopathy, HypertrophicCorxel Pharmaceuticals · NCT06116968 · 40 enrolled · China
- May 9, 2024Phase 3 study in PediatricCytokinetics · NCT06412666 · 65 enrolled · United States, Canada, Italy and more
- Jun 10, 2025Bayer's first study: phase 3 study in Cardiomyopathy, HypertrophicNew to BayerBayer · NCT07023341 · 36 enrolled · Japan
- Oct 13, 2026Primary completion moved from 2028-03 to 2029-03Date moved laterphase 3 · +12 months · NCT04848506
Ahead
- Mar 2029Primary completion: phase 3 study in Cardiomyopathy, HypertrophicCytokinetics · NCT04848506
- Jan 2030Primary completion: phase 3 study in PediatricCytokinetics · NCT06412666
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 11 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07023341Cardiomyopathy, Hypertrophic · Japan | 3 | Active, not recruiting | Bayer | Jul 14, 2026 | 36 |
| NCT06412666Pediatric · United States, Canada, Italy and more | 3 | Active, not recruiting | Cytokinetics | Jan 2030 | 65 |
| NCT06116968Cardiomyopathy, Hypertrophic · China | 3 | Completed | Corxel Pharmaceuticals | Oct 20, 2025 | 40 |
| NCT06081894Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy · United States, Argentina, Australia and more | 3 | Active, not recruiting | Cytokinetics | Aug 31, 2026 | 500 |
| NCT05924815Healthy Participants · United States | 1 | Completed | Cytokinetics | Nov 14, 2023 | 44 |
| NCT05767346Cardiomyopathy, Hypertrophic · United States, Brazil, Canada and more | 3 | Completed | Cytokinetics | Feb 28, 2025 | 175 |
| NCT05186818Cardiomyopathy, Hypertrophic · United States, China, Czechia and more | 3 | Completed | Cytokinetics | Nov 10, 2023 | 282 |
| NCT04848506Cardiomyopathy, Hypertrophic · United States, Argentina, Australia and more | 3 | By invitation | Cytokinetics | Mar 2029 | 900 |
| NCT04783766Cardiomyopathy, Hypertrophic · China | 1 | Completed | Corxel Pharmaceuticals | Aug 5, 2021 | 28 |
| NCT04219826Cardiomyopathy, Hypertrophic · United States, Italy, Netherlands and more | 2 | Completed | Cytokinetics | Feb 28, 2023 | 96 |
| NCT03767855Cardiomyopathy, Hypertrophic · United States | 1 | Completed | Cytokinetics | Jan 3, 2020 | 114 |
How it is read
Names in the registry
- “Aficamten”, 4 entries
- “BAY3723113”, 1 entry
- “Aficamten (5 - 20 mg)”, 1 entry
- “Aficamten (CK-3773274) (5 mg, 10 mg, 15 mg and 20 mg)”, 1 entry
- “Aficamten (5 mg, 10 mg, 15 mg, and 20 mg)”, 1 entry
Conditions, from the studies’ own filings
- Cardiomyopathy, Hypertrophic, 10 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.